Doug Balut joins Meltwater as Senior Vice President of Global Alliances and Partnerships
SAN FRANCISCO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Meltwater, a leading global provider of social, media and consumer intelligence, today announces the appointment of Doug Balut as Senior Vice President of Global Alliances and Partnerships.
In this pivotal role, Doug will spearhead the development of a dynamic partner ecosystem, build a robust channel sales organization, and drive go-to-market strategies, all aimed at propelling Meltwater's growth, creating more value for customers and solidifying its position as an enterprise-grade suite of solutions.
Balut brings more than 25 years of experience and an impressive track record in the technology industry to Meltwater, most recently serving as the Senior Vice President of Global Alliances at Sprinklr. In his role at Sprinklr, he played a central role in establishing a partner organization and a successful methodology for growth, culminating in Sprinklr's IPO in 2021. Additionally, Balut is a three-time recipient of CRN Channel Chiefs Award in 2021, 2022, and 2023.
Prior to his tenure at Sprinklr, Balut held a number of sales leadership positions in both direct and indirect partner sales at Cisco, leading teams across the globe and partnering with organizations including SAP, Accenture, Deloitte, IBM, Intel, and more.
At Meltwater, Balut will be integral to the company's growth and commitment to customers, focusing on establishing a mutually beneficial partner program, fostering strategic relationships that put Meltwater customers at the core of success, leveraging social channel partnerships and ensuring that clients reap the full benefits of Meltwater's offerings.
Balut expressed his enthusiasm for joining Meltwater, saying, "I am really excited to join Meltwater and to build out a new partner ecosystem to support Meltwater’s growth and Enterprise transformation plans. The timing is right to focus on large account growth across the globe, as the next evolution in Meltwater’s exciting history. Partnerships are a catalyst for this growth, and I am ready to build an organization and network of influential partners to help achieve those goals."
“I am thrilled to welcome Doug Balut to the Meltwater team as our new SVP of Alliances & Partnerships. Doug brings over 25 years of experience in building and leading strategic alliances, channel sales, and business development in the SaaS industry. He has a proven track record of driving revenue growth, expanding market reach, and creating value for customers and partners. Doug will play a key role in strengthening our partner ecosystem and accelerating our global expansion. I look forward to working with him to deliver the best media, social and consumer intelligence solutions to our clients,” said John Box, CEO of Meltwater.
For more information, please contact:
Corporate Communications Director
Meltwater empowers companies with a suite of solutions that spans media, social, consumer and sales intelligence. By analyzing ~1 billion pieces of content each day and transforming them into vital insights, Meltwater unlocks the competitive edge to drive results. With 27,000 global customers, 50 offices across six continents and 2,300 employees, Meltwater is the industry partner of choice for global brands making an impact. Learn more at meltwater.com.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Resultat af auktion over skatkammerbeviser 29. november 202329.11.2023 10:25:38 CET | pressemeddelelse
Bud, salg, skæringsrenter og pris fremgår af nedenstående oversigt: ISINBud mio. kr. (nominelt)SalgSkæringsrente (pct.)Pro-rataKurs98 19237 SKBV 24 / I1.220 960 3,500 100 %99,1230 98 19310 SKBV 24 / II1.760 1.020 3,450 100 %98,2580 I alt2.980 1.980 Salget bliver afviklet den 1. december 2023
Result of the auction of treasury bills on 29 November 202329.11.2023 10:25:38 CET | Press release
Bids, sales, stop-rates and prices are presented in the table below: ISINBid Mill. kr. (nominal)SaleStop-rate (per cent)Pro-rataPrice98 19237 DKT 01/03/24 I1,220960 3.500 100 %99.1230 98 19310 DKT 03/06/24 II1,760 1,020 3.450 100 %98.2580 Total2,980 1,980 The sale will settle 1 December 2023
Dassault Aviation Wins Choiseul “Strategic Company” Award29.11.2023 10:21:57 CET | Press release
Dassault Aviation Wins Choiseul “Strategic Company” Award (Saint-Cloud, November 29, 2023) – Dassault Aviation is particularly proud to have received the 2023 Strategic Company Award as part of the Institut Choiseul’s Sovereignty Initiative. The institute believes that strategic companies represent one of the many facets of national strength. Award recipients are known for their capacity to effectively mobilize resources and know-how, and to provide solutions that meet national priorities. They are a cornerstone of French strategic heritage. Dassault Aviation is an industrial architect and complex systems integrator, a developer of strategic technologies, a major national exporter, a core shareholder of the Thales Group and a vital player in an industrial landscape that includes hundreds of business and service partners. The company is at the core of the French sovereign defense ecosystem. Dassault Aviation is also the only non-American company that manufactures high-end business jets.
Company announcement no 17/2023 Interim Report Q3 202329.11.2023 10:20:00 CET | Press release
Interim Report Q3 2023 EBITDA fixed herd prices (FHP) for Q3 2023 increased to 13.663 mEUR (Q3 2022: 10.463 kEUR), corresponding to an EBITDA margin FHP of 36.3% (Q3 2022: 32.5%). The quarterly EBITDA in Q3 2023 increased by 3.201 kEUR (compared to Q3 2022). Nevertheless, this consist of many parts this quarter: Russia harvest negative with 2,7 mEUR (from 4,1 to 1,5 mEUR) whereas remaining Russian business compensate positive with 3,0 mEUR partly due to FX (cost in EUR lower), Lithuania negative effects from one-off subsidy in Q3 2022 (2,5 mEUR), but combined sales/feed with positive effect of 4.9 mEUR and lower cost levels with 0.5 mEUR driven by utilities. Sales prices combined down, as they in Q3 2023 were 1.59 EUR/kg live weight, down from 1.62 EUR/kg Q2 2022 equal to EUR 0,8m, but EURRUB effects this picture highly as Lithuanian sales prices in EUR is up 23% and Russian in RUB is up 13%. Feed prices in Q3 2023 were 261 EUR/T (compared to 332 EUR/T Q3 2022). End September 2023 on h
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®29.11.2023 10:00:00 CET | Press release
The study, assessing pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® (golimumab) in healthy adult subjects, met its primary endpoint Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive top-line results from a pharmacokinetic study for AVT05, a biosimilar candidate to Simponi® and Simponi Aria® (golimumab). The study, which assessed the pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi in healthy adult subjects, met its primary endpoints. “These results demonstrate the strength of our platform approach to biosimilars development and manufacture, combining a well-designed and executed clinical study with the design of a high-quality manufacturing process and strong analytical capabilities,” said Joseph McClellan, Chief Scientific Officer. “As we progress more biosimilar candidates through clinical development and approval, w